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Abstract
Background: At least half of all adult women will experience infective cystitis (urinary tract infection: UTI) at least
once in their life and many suffer from repeated episodes. Recurrent urinary tract infection (rUTI) in adult women is
usually treated with long-term, low-dose antibiotics and current national and international guidelines recommend
this as the ‘gold standard’ preventative treatment. Although they are reasonably effective, long-term antibiotics can
result in bacteria becoming resistant not only to the prescribed antibiotic but to other antimicrobial agents. The
problem of antimicrobial resistance is recognised as a global threat and the recent drive for antibiotic stewardship
has emphasised the need for careful consideration prior to prescribing antibiotics. This has led clinicians and
patients alike to explore potential non-antibiotic options for recurrent UTI prevention.
Design /methods: This is a multicentre, pragmatic, patient-randomised, non-inferiority trial comparing a non-
antibiotic preventative treatment for rUTI in women, methenamine hippurate, against the current standard of daily
low-dose antibiotics. Women who require preventative treatment for rUTI are the target population. This group is
comprised of those with a diagnosis of rUTI, defined as three episodes in 1 year or two episodes in 6 months, and
those with a single severe infection requiring hospitalisation. Participants will be recruited from secondary care
urology / urogynaecology departments in the UK following referral with rUTI. Participants will be followed up
during a 12-month period of treatment and in the subsequent 6 months following completion of the prophylactic
medication. Outcomes will be assessed from patient recorded symptoms, quality of life questionnaires and
microbiological examination of urine and perineal swabs. The primary outcome is the incidence of symptomatic
antibiotic-treated UTI self-reported by participants during the 12-month period of preventative treatment. Health
economic outcomes will also be assessed to define the cost-effectiveness of both treatments. A qualitative study
will be conducted in the first 8 months of the trial to explore with participants/non-participants’ and recruiting
clinicians’ views on trial processes and identify potential barriers to recruitment, reasons for participating and non-
participation and for dropping out of the study.
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Background
Recurrent urinary tract infection (rUTI) in adult women
is one of the most common infections in humans. Bac-
teria from the vagina or faecal matter inoculate the peri-
urethral area, then the bladder, causing symptoms of
cystitis. The lifetime risk of a urinary tract infection
(UTI) is around 40% in adult women and the incidence
peaks in the third and ninth decades. The annual inci-
dence of a single UTI is 3% [1] with up to 44% of these
women experiencing recurrence within 1 year [2]. This
equates to an affected population of over 300,000
women in 1 year in the UK [3].
The prophylactic treatment of rUTI with extended
courses of low-dose antimicrobial therapy is standard
practice and a meta-analysis from the Cochrane Collabor-
ation shows that this reduces recurrence rate by up to
80% [4]. However, antibiotics are the main driving force in
the development of antibiotic resistance and can lead to
resistance not only of the causative microorganisms but
also of the commensal flora [5]. Prudent antibiotic pre-
scribing (stewardship) is one of the cornerstones of UK
and international strategies to prevent antimicrobial resist-
ance [6, 7] and recent guidelines have identified that
‘repeated/prolonged treatment with antibiotics’ is con-
tributory to the development of this serious health prob-
lem [8]. Alternative, non-antibiotic treatments for the
prevention of rUTI have the potential to improve public
health by minimising the development of antimicrobial re-
sistance in bowel reservoirs and well-designed trials are
needed to demonstrate their effectiveness.
The current body of evidence and the
contribution of this study
Prophylactic antibiotics constitute the current standard
of care for the preventative treatment of rUTIs and are
recommended for this use by both UK and European
guidelines [8, 9] .The largest meta-analysis examining
the efficacy of prophylactic antibiotics reveals an 85% re-
duction in symptomatic UTI over placebo (RR 0.15, 95%
CI 0.08 to 0.28) [4]. This meta-analysis included 19 stud-
ies with data from 1120 women. The authors concluded
that continuous antibiotic prophylaxis for 6–12 months
reduced the rate of UTI during prophylaxis when com-
pared to placebo. There were, however, more adverse
events (AEs) in the antibiotic group and these included
vaginal and oral candidiasis and gastrointestinal symp-
toms. The observation that following treatment the rate
of symptomatic UTI returned to similar levels in both
women taking prophylactic antibiotics and those receiv-
ing placebo comes from only two studies. This does,
however, suggest that the benefits of antibiotics are not
sustained following cessation of treatment.
Methenamine hippurate has been the subject of a
meta-analysis from the Cochrane Collaboration [10] and
this included 13 studies comprising data from 2043 pa-
tients. The reduction in UTIs was of the order of 76%
(RR 0.24, 95% CI 0.07 to 0.89). The authors did however
comment that the quality of the included studies was
mixed and that pooled estimates for the major outcome
measures were not interpretable because of underlying
heterogeneity. Nevertheless, they were able to assert that
methenamine hippurate may be effective for preventing
UTI in patients without renal tract abnormalities, par-
ticularly when used for short-term prophylaxis. The rate
of AEs was low, but poorly described. The need for
large, well-conducted clinical trials to clarify the effect-
iveness of methenamine hippurate in the setting of pre-
vention of UTIs was highlighted.
Although continuous antibiotic treatment has been
shown to prevent rUTIs [4] previous randomised trials
have demonstrated an associated threefold increase in
the incidence of antimicrobial resistance compared with
placebo [11]. Several studies have confirmed the emer-
gence of resistant organisms in the faecal reservoir and
urine of women who take prolonged antibiotics [11, 12].
The resistance pattern observed was not confined to the
prescribed antibiotic but to a range of other antibiotic
agents commonly used to treat symptomatic UTI [1].
Furthermore the detection of resistant microorganisms
can occur after just a few weeks of prophylactic anti-
biotic therapy [11]. The use of effective non-antibiotic
UTI prevention strategies will reduce risk to patients of
emergence of resistant organisms and subsequent
difficult-to-treat clinical infection with these bacteria.
The incidence of antimicrobial multi-resistance within
post-menopausal women suffering from rUTI is around
25% and was shown to rise to more than 80% following
prolonged antibiotics [5].
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The advisability of using non-antibiotic preventative
treatments for rUTI has been highlighted by recent UK,
European and US guidelines to reduce the ‘collateral dam-
age’ of antibiotic use by minimising risk of resistance devel-
opment [6]. Policy-makers in the UK and Internationally
have included antibiotic avoidance and prudent antibiotic
prescribing as key components of action plans and
strategies to reduce antimicrobial resistance [13, 14]. A
well-designed research study providing robust evidence of
at least equivalent effectiveness of non-antibiotic treat-
ment is needed to further inform guideline-writers and
policy-makers and allow recommendation of alternative
treatments avoiding prolonged antibiotic use.
In addition to the problem of antimicrobial resistance
within an individual’s faecal reservoir there is a wider
public health concern regarding the continued emer-
gence of healthcare-associated infections (HAI) initially
focussed on methicillin resistant Staphylococcus aureus
(MRSA) and Clostridium difficile infection (CDI) and
more recently other types of multi-resistant organisms
including those producing extended-spectrum beta lac-
tamases (ESBL). The predominant uropathogen, Escheri-
chia coli (E. coli), is the subject of a recent article
identifying the overuse of non-prescription antibiotics in
Asia as a potential causative factor for the development
of a new mechanism of ESBL antibiotic resistance
detected in the UK [15]. Limiting the use of
broad-spectrum antibiotics is a key measure in address-
ing this problem, and has been the driver for recent UK
guideline updates [8]. The development of antimicrobial
stewardship programmes which encourage prudent anti-
biotic prescribing has already been shown to reduce
antibiotic use and consequently the incidence of HAI
which until recently was increasing [16, 17]. Avoidance
of antibiotic administration, where possible, is believed
to be the single most important factor leading to the ob-
served decline in HAI in Scotland [17]. A positive result
from our study will further encourage avoidance of anti-
biotic prescription by providing high-level evidence of
efficacious non-antibiotic alternatives reducing the
chance of emergence of multi-resistant UTIs.
Our study will address the question of whether the use
of the urinary antiseptic methenamine hippurate (a
non-antibiotic preventative treatment) results in an
equivalent reduction in rate of symptomatic UTIs com-
pared to prophylactic antibiotic therapy in women suf-
fering from rUTI. In addition, we will assess the
longer-term effectiveness of these two treatments by fol-
lowing up all participants for 6 months after treatment.
We will also evaluate both treatments in terms of their
cost-effectiveness and effect on overall quality of life
(QoL). Furthermore, secondary outcomes will assess
whether use of this alternative preventative treatment re-
duces the development of antimicrobial resistance within
uropathogens that is associated with antibiotic use in-
cluding the main pathogen E. coli. Using health eco-
nomic analysis, we aim to value this benefit to women
suffering rUTI and to the wider NHS.
Why this research is needed now
A recent meta-analysis reviewed the evidence for
non-antibiotic treatments as prophylaxis against rUTI but
the results were disappointing, mainly due to paucity of
evidence [18]. One of the conclusions in this report was
that ‘Although sometimes statistically significant, pooled
findings for the other (non-antibiotic) interventions should
be considered tentative until corroborated by more re-
search’. It would appear that one of the barriers to clini-
cians recommending non-antibiotic alternatives for the
treatment of rUTI is the lack of currently available clinical
evidence. The campaign for antibiotic stewardship and
more prudent prescribing of antibiotic agents can only be
strengthened by further work exploring effectiveness of
non-antibiotic alternatives. A further conclusion from this
meta-analysis was that ‘Large head-to-head trials should be
performed to optimally inform clinical decision-making’.
The most recent guideline published on the subject of
UTI is the 2012 Scottish Intercollegiate Guideline Net-
work (SIGN) guideline 88 [8] which forcibly illustrates
why our proposed study is essential and needed promptly.
The literature review carried out prior to formulation of
this document identified ‘considerable evidence of practice
variation’ and variation in ‘initiation of antibiotic treat-
ment’ for UTI. In addition, one of the constant themes in
this report is the need to avoid ‘unnecessary antibiotic
prescribing’ which is associated with ‘clinical adverse
events including Clostridium difficile infection (CDI) or
methicillin-resistant Staphylococcus aureus (MRSA) infec-
tion, and the development of antibiotic-resistant (E. coli)
UTIs’. The UK antimicrobial resistance strategy and action
plan [6] states that ‘the increasing prevalence of antimicro-
bial resistant micro-organisms is causing international
concern’ and identifies that ‘the emergence of resistance
represents adaptive selection by micro-organisms which is
an inevitable result of therapeutic use of antimicrobial
agents’. This document reflects an urgent need for pru-
dent antibiotic use as one of three key elements of the
strategy to control antibiotic resistance. The ALTAR study
aims to provide high-level contemporary evidence of the
relative effectiveness of a non-antibiotic UTI prevention
treatment compared to the standard treatment of pro-
longed, low-dose antibiotics within a UK population of
women with rUTI in a routine NHS care setting.
Design/methods
The ALTAR trial is a robust, pragmatically designed trial
to evaluate the clinical benefit and cost-effectiveness of
the best candidate alternative treatment for the prevention
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of rUTI, the urinary antiseptic methenamine hippurate
compared to the standard treatment of low-dose prophy-
lactic antimicrobial therapy. Outside of the trial medica-
tion, both groups will receive usual care and any
breakthrough UTI will be treated by discrete courses of
antibiotic treatment.
The null hypothesis being tested is that the
non-antibiotic treatment (methenamine hippurate) is in-
ferior to the standard treatment of an extended course
of prophylactic antibiotic for the prevention of rUTI in
women and less cost-effective to the NHS. The alterna-
tive hypothesis is that methenamine hippurate is as good
at preventing UTI and is as cost-effective as antibiotic
prophylaxis. We have chosen to investigate the possible
non-inferiority of methenamine hippurate in order to
clarify an alternative treatment choice to antibiotics in
treating rUTIs, which may prevent increases in
antibiotic-resistant strains of infection.
Estimates of prevalence, effectiveness and harms from
Cochrane reviews have informed the power calculation
conservatively based on what we, guided by a patient
panel, considered to be a minimum threshold difference
that would drive patient and clinician acceptability to-
gether with change of practice prompted by inclusion of
trial results in future meta-analyses and guidance for
management of rUTI in the NHS and internationally.
The anticipated trial flow for participants is shown in Fig. 1
and the trial schedule of procedures is shown in Table 1.
Objectives
Primary objective
The primary objective is to:
 Determine the relative clinical effectiveness and
cost-effectiveness for the NHS of two types of li-
censed preventative treatments for women with re-
current uncomplicated urinary tract infection (rUTI)
over a 12-month treatment period
Secondary objectives
The secondary objectives are to determine:
 The relative impact on the incidence of
symptomatic antibiotic-treated UTI self-reported by
patients during the 6-month follow-up period after
completion of 12 months of allocated treatment
 The total number of days spent on urinary specific
antibiotics (prophylactic or treatment) during the 12-
month treatment period and 6 months of follow-up
 If there is any longitudinal ecological change in
terms of phenotype and genotype of bacteria and
their resistance patterns in isolates from individual
participant’s (1) urine and (2) faecal reservoir during
the 12-month treatment period and in the 6 months
following completion of treatment
 The number of microbiologically proven UTIs
during the 12-month treatment and 6-month
follow-up periods
 The incidence of asymptomatic bacteriuria (ABU)
during the study period
 The incidence rate of hospitalisation due to UTIs
during the study period
 Overall patients’ satisfaction with antibiotic vs
antiseptic treatment
 Patients’ and clinicians’ views regarding trial
processes and participation via an embedded
qualitative study
 The incremental cost per Quality-adjusted Life Year
(QALY) gained at 18-month periods based on re-
sponses to the EuroQol 5 Dimension Questionnaire
(EQ5D-5 L)
 The incremental costs to the NHS, personal social
services measured at the end of the 18-month study
period
 The relative health economic efficiency over the
patient’s lifetime using a modelling exercise
Primary outcome measures
The primary outcome measures for the ALTAR trial are:
1. Incidence of symptomatic antibiotic-treated UTI
self-reported by participants and verified where ne-
cessary from medical records during the 12-month
period of preventative treatment
2. Incremental cost per QALY gained during the 12-
month treatment period. Incremental costs to the
NHS, personal social services, and the patient at
12 months
Occurrence of a symptomatic UTI will be captured by:
 Participants completing a UTI record when
experiencing a UTI
 Face-to-face appointments and Case Report Form
(CRF) completion at 3, 6, 9 and 12 months
 Participant questionnaires completed at 3, 6, 9 and
12 months
 Monthly contact with the local site trial team
 End-of-trial review and primary care record review
The incremental costs to the NHS, personal social ser-
vices and the patient at 12 months will be captured by:
 Treatment costs of drugs and healthcare services
from standard NHS sources such as the British
National Formulary (BNF)
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 Health Resource Use Questionnaires at 3, 6, 9 and
12 months
Secondary outcome measures
1. The number of symptomatic, antibiotic-treated
UTIs self-reported by participants in the 6-month
follow-up period after completing the allocated pre-
ventative therapy
2. Total antibiotic use during the study period,
reported by patients and verified where necessary
from medical records
3. Phenotype and genotype of Escherichia coli (E. coli)
isolated from urine and perineal swabs sent by
participants directly to the central reference
laboratory
4. The number of microbiologically confirmed UTIs
occurring during both the 12 months of treatment
and the subsequent 6 months of follow-up. A
Fig. 1 Trial flow chart
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positive culture will be classified according to stand-
ard Public Health England (PHE) definitions; the la-
boratory report of two isolates at ≥105 cfu/mL or a
single isolate at ≥104 cfu/mL
5. Presence of ABU identified by urine culture
performed at patient visits for study follow-up. ABU
is defined as the presence of bacteria in the urine in
the absence of symptoms suggestive of UTI. For the
purposes of this study, a positive culture is defined
in line with the routine PHE definitions above
6. The incidence rate of hospitalisation due to UTIs
during the treatment and follow-up phases of the
study
7. Overall satisfaction with treatment measured by
Treatment Questionnaire on Satisfaction with
Medication (TQSM)[19] administered at both the
end of treatment (12 months) and then again at the
end of follow-up (18 months)
8. Qualitative analysis of patients’ and clinicians’ views
regarding trial processes and participation
9. QALYs based on responses to the EQ5D-5 L at 3, 6,
9, 12, 15 and 18 months and after a UTI episode
10. Treatment costs for drug and healthcare services
from a standard NHS source such as the BNF and
published tariffs from NHS reference costs
11. Health Resource Use Questionnaire at 3, 6, 9, 12,
15 and 18 months. Incremental cost per QALY
gained during the total 18-month trial period. In-
cremental costs to the NHS, personal social ser-
vices, and the patient at 18 months
12. Costs and QALYs will be combined in a cost-utility
analysis for both a ‘within’ trial analysis and mod-
elled over the patient’s lifetime using previously de-
veloped methods and data from other relevant
randomised controlled trials (RCTs) that collected
patient costs
Table 1 Schedule of procedures
Procedures Screening Baseline Treatment phase Follow up
3 months 6 months 9 months 12 months At time
of UTI
Monthly
checks
15 months 18 months
Informed consent X
Demographics X Xa
Medical history X
Physical examination X
eGFR and LFTs (a sample for DNA
will be taken at one of these time
points)
X Xa X X X X X X
MSU (local laboratory) X X X X X X X X
MSU (central laboratory) X X X X X X X X
Perineal swab X X X X
Concomitant medications X Xa
Eligibility assessment X
Randomisation X
Dispensing of trial drugs X X X X
Compliance X X X X X X X X
UTI record X
UTI questionnaire X X X X X X
EQ5D-5 L X X X X X X X X
Health Resource Use Questionnaire X X X X X X
TQSM X X
Adverse event assessments X X X X X X X
CRF completion X X X X X X X X X X
Qualitative interviews Xb Xc
CRF Case Report Form, DNA deoxyribonucleic acid, eGFR estimated glomerular filtration rate, EQ5D L EuroQoL 5 Dimension Questionnaire, LFT liver function tests,
MSU mid-stream urine, TQSM Treatment Questionnaire on Satisfaction with Medication, UTI urinary tract infection
aScreening data values may be used for baseline if taken within 14 days from date of randomisation. b15 patients who declined to participate in main study but
consented to interview study. c15 patients who do not complete the treatment and 15 patients who stay in the study up to 6 months post randomisation will be
interviewed. Time points will vary
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These will be captured by:
 Participants completing a UTI record when
experiencing a UTI
 At face-to-face appointments and CRF completion
at 3, 6, 9, 12, 15 and 18 months
 In participant questionnaires completed at 3, 6, 9
and 12 months
 Monthly contact with the local site trial team
 Results from a mid-stream specimen of urine (MSU)
and perineal swabs
 End-of-trial review and primary care record review
Study setting
Large, secondary care urology centres with a consistent
clinical assessment pathway for women with rUTI will
be selected as sites for this multicentre clinical trial.
Centres will be sufficiently resourced and have a proven
track record of delivering clinical research with estab-
lished links to their respective Clinical Research Net-
works (CRN). The principal investigator (PI) or
delegated individual will be responsible for coordinating
participant recruitment by screening women with rUTI
who are routinely referred from primary care to these
centres. We initially plan to open four sites and we will
consider opening further sites if the rate of recruitment
is slower than anticipated.
Patient identification
We will aim to ensure that all adult women referred to
each site with rUTI are aware of the study prior to their
clinic appointment and those eligible can consider
whether they wish to participate prior to assessment.
Each research site lead will publicise the study within
their own departments and referral catchment areas and
ensure that colleagues in allied specialities, such as uro-
gynaecology and nephrology, who may receive referrals
of women with rUTI, are aware of the study and are
willing to identify potential participants. We will use
established CRN links to ensure that referring GPs are
aware of the study; can identify potential eligible partici-
pants and direct referrals accordingly, we will register
general practices or other secondary sites as participant
identification centres (PIC) if needed. All sites will have
an established clinical research track record and effective
infrastructure in place for patient recruitment.
In order for the results from the ALTAR study to be
generalisable across the wider NHS, the demographic
mix of patients recruited to the study must reflect that
of patients currently being referred to urologists. Recur-
rent UTI is generally defined as three episodes of infec-
tion within a 12-month period [8] and the patient group
most affected by rUTI is adult women, making up over
80% of all people presenting with UTI [15]; this will
constitute the majority of our target population. We
have expanded the inclusion criteria to other groups that
would also be considered for antibiotic prophylaxis in-
cluding women who have had two episodes of UTI in
the preceding 6 months and patients who have had one
episode of serious UTI resulting in hospitalisation in the
preceding 12 months. Furthermore, patients who are be-
ing treated by their general practitioner (GP) in primary
care will also be identified by liaison of the lead clinician
in each site with primary care leads within Local Clinical
Research Networks (LCRNs).
ALTAR study sites will consist of large UK urology/
urogynaecology centres, with the majority of referrals
coming from primary care through the standard NHS
‘Choose and Book’ pathway. These centres have
well-defined existing clinical pathways in place for the
investigation of such patients which initially focusses on
the exclusion of underlying structural or functional ab-
normalities of the urinary tract. This is usually done by
renal tract ultrasound scan (USS) and an endoscopic
examination of the bladder under local anaesthesia (flex-
ible cystoscopy). A recent local audit in Newcastle (un-
published data, n = 200) has revealed that contributory
structural or functional abnormalities are detected in
less than 10% of patients. Therefore, we estimate that
approximately 90% of patients referred with rUTI to
these centres will be eligible to be approached for inclu-
sion to the ALTAR study. We will compare ratios of
screened to randomised patients throughout the trial
which will enable us to estimate recruitment rates and
ensure that targets are met.
PICs will be considered as a means to maximise re-
cruitment at each site. Participants will be identified by
the PIC and information about the study will be pro-
vided. Any participants interested in the study will be re-
ferred to the main site for possible recruitment into the
study through the usual recruitment procedures.
Recruitment will be carried out by research staff in each
of the centres and will involve a clear explanation of the
trial including the background, study protocol and aims.
Study design and duration
This is a multicentre, pragmatic patient-randomised,
non-inferiority trial comparing two treatments for the pre-
vention of rUTI in women during a 12-month period of
treatment and in the 6 months following treatment com-
pletion. The standard treatment is once-daily prophylactic
antibiotic, using either trimethoprim 100 mg, nitrofuran-
toin 50 or 100 mg or cefalexin 250 mg once daily for
12 months which are the recommended drugs licensed for
this purpose. The choice of antibiotic will be decided by
considering previous bacterial sensitivities, safety, and pa-
tient or clinician preference. The alternative (experimental)
treatment is a 1-g twice daily dose of the orally
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administered urinary antiseptic methenamine hippurate for
12 months. Participants in both arms would continue to
receive treatment courses of antibiotic for UTI as needed.
Target population
The target population for the ALTAR trial are women
(aged > 18 years) with recurrent UTI, for whom prophy-
lactic antibiotics would be considered as a therapeutic
option, e.g. at least three episodes of symptomatic
antibiotic-treated urinary infection in the previous
12 months, two episodes of UTI in the last 6 months or
a single occurrence of severe UTI requiring hospital ad-
mission in the preceding 1 year.
Inclusion criteria
The inclusion criteria are as follows:
 Women aged 18 years and over
 Women with rUTI who, in consultation with a
clinician, have decided that prophylaxis is an
appropriate option (to include women who have
suffered at least three episodes of symptomatic UTI
within the preceding 12 months or two episodes in
the last 6 months or a single severe infection
requiring hospitalisation)
 Able to take a once daily oral dose of at least one of
nitrofurantoin, or trimethoprim or cefalexin
 Able to take methenamine hippurate
 Women who agree to take part in the trial but who
are already taking methenamine or antibiotic
prophylaxis will be consented for participation and
will stop their preventative therapy for a 3-month
washout period. They will then be reassessed and, if
still eligible, undergo baseline assessment and
randomisation
 Able to give informed consent for participation in
the trial
 Able and willing to adhere to an 18-month study period
Exclusion criteria
The exclusion criteria are as follows:
 Women who are unable to take methenamine
hippurate, e.g. known allergy to methenamine
hippurate, severe hepatic impairment (Child-Pugh
class C, score of 10 or more, gout, estimated
glomerular filtration rate (eGFR) < 10 mL/min,
Proteus spp. as a consistent proven causative
organism for rUTIs
 Women who are unable to take nitrofurantoin and
trimethoprim and cefalexin
 Women with correctable urinary tract abnormalities
that are considered to be contributory to the
occurrence of rUTI
 Presence of symptomatic UTI – this will be treated
and symptoms resolved prior to randomisation
 Pregnancy or intended pregnancy in next 12 months
 Women who are breast-feeding
 Women already taking methenamine or antibiotic
prophylaxis and declining a 3-month washout period
Screening, recruitment and consent procedures
Screening clinical records and face to face
Clinical staff at each site will identify eligible participants
through direct contact or by searches of electronic records
held in each trust. They will then give or send potentially
eligible patients brief study information. Interested poten-
tial participants can then agree to be approached by re-
search staff and provided with further study information.
Trial invitation information will include brief details of the
need and purpose of the study and eligibility criteria. It
will emphasise the pragmatic nature of the study and give
a realistic indication of the burden to participants. All pa-
tients given trial information will be recorded in the
screening logs at each site. All subjects who agree to con-
sider participation will be seen by local research staff or
the trial coordinator at the respective site to go through
the consent and randomisation procedure. A CRF will be
initiated and baseline data collected.
A screening log will be kept by local site research staff to
document details of subjects invited to participate in the
study and reasons for non-participation. Non-identifying
patient details and reasons for non-participation will be
uploaded to the study electronic Case Report Form (eCRF)
for subsequent analysis. The log will also ensure that poten-
tial participants who are ineligible or decline participation
are approached only once. Participants who do not respond
to written information about the study may be contacted a
second time to ensure that they have received the informa-
tion and been given the opportunity to participate.
Consent
Participants will be consented for randomisation, trial
participation, consent regarding telephone interviews,
storage of blood, urine and swab for future research and
whether they agree to be approached for further re-
search studies in this area.
All participants will undergo a process of informed
consent undertaken by appropriately trained staff from
the main trial sites. The consent process will include
provision of balanced written information concerning
the need and overall benefit of the trial followed up by
discussion with a local trial coordinator.
In relation to the qualitative interviews, recruiting staff
will also explain why it is important to understand why
people do and do not participate and how an interview
study can help to improve the way that trials are con-
ducted. Participants who are willing to be approached
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will be provided with a separate information sheet about
the interview study.
Following receipt of information about the study, par-
ticipants will be given at least 24 h and up to as much
time as they need to decide whether or not they would
like to participate. Written informed consent will always
be obtained prior to randomisation. The participant will
specifically consent to their GP being informed of their
participation in the study. The right to refuse to partici-
pate without giving reasons will be respected.
During study set up we will consider requests for trial
participant literature including the information sheet
and consent form to be translated into other languages.
Ability of the participant or their carer to complete the
primary outcome questionnaires in English will be re-
quired for trial participation. If local NHS circumstances
permit, sign interpreters will be arranged for all visits
with patients who require them for deaf patients wishing
to take part in the study. Interpreters will be used where
necessary to explain the consent form and information
sheet; great priority will be placed on finding the most
direct means of communication. If local research staff
are in any doubt with regards to patient understanding
of crucial aspects of the trial or ability to collect the out-
come measures in English, then consent for randomisa-
tion will not be sought.
Participants will be given the option of consenting to
storage of blood, urine and a perianal swab for future re-
search. They will also be asked if they would be willing
for the inclusion of data collected for this study in future
research. Any further research would be subject to sep-
arate review by an ethics committee.
Randomisation
Randomisation will be administered centrally by the
Newcastle Clinical Trials Unit (CTU) secure web-based
system. Permuted random blocks of variable length will
be used to allocate participants 1:1 to the antibiotic and
antiseptic groups. An individual not otherwise involved
with the study will produce the final randomisation
schedule. Stratification by two variables; prior frequency
of UTI (less than four episodes per year or more than
four episodes per year), and menopausal status of
participants (pre-menopausal or menopausal/post-men-
opausal) will be performed prior to randomisation to en-
sure balanced allocation within these factors.
Following randomisation an appointment will be ar-
ranged, facilitated by trial staff, with the prescribing clin-
ician to commence allocated treatment and ensure
continued supply for the 12-month treatment period
usually through hospital prescription or via the partici-
pant’s GP. The antibiotic selected for use as prophylaxis
will be chosen by the patient and clinician with regard
to individual participant characteristics, local guidance
and standardised trial information with preferred agents
being: nitrofurantoin first, trimethoprim second, cefa-
lexin third.
Blinding
There is no participant blinding in this study. The mem-
bers of the local research team that will carry out the
follow-up process will not be blinded to the allocated
treatment for each participant. We will, however, try to
ensure that central trial staff will be unaware of allocated
group in data reported during the trial where possible.
Intervention
Apart from random allocation to either option, all par-
ticipants will receive usual care including use of
on-demand discrete treatment antibiotic courses for
UTI. We have formulated a recruitment plan to progres-
sively build to a target of 240 participants over an
18-month recruitment window.
Methenamine hippurate
For those women randomised to receive methenamine
hippurate a twice daily dose of 1 g to be taken 12 h apart
will be prescribed for 12 months (as recommended in
the BNF). An eGFR of less than 10 mL/min will be an
exclusion criterion for the study. Other exclusion criteria
will be patients with gout which is a contra-indication to
treatment with methenamine and those with liver dys-
function as determined by pre-study serum liver func-
tion tests (LFT) (analysis of blood sample). Patients
randomised to receive methenamine hippurate or anti-
biotic prophylaxis will have blood samples taken at 3, 6,
9 and 12 months to monitor kidney and liver function
(eGFR and LFT). If there are any abnormalities in these
tests during the period of treatment then a further sam-
ple will be taken at 18 months to ensure that these have
resolved. If clinically indicated, blood tests may be more
frequent. If there are specific and intolerable side-effects,
such as nausea, gastrointestinal disturbance, itching or
skin rashes, then participants will be given the opportunity
to discontinue treatment and be offered an alternative
treatment which may include prophylactic antibiotic. This
information will be recorded and the participant will con-
tinue on the study. If a participant in the methenamine
group develops symptoms and signs suggestive of break-
through UTI then they will seek treatment in their usual
way, predominantly by contacting their GP and starting a
discrete treatment course of antibiotics. They will be re-
quested to submit a urine sample via their healthcare
practitioner, and to send a urine sample to the central ref-
erence laboratory before starting treatment, and will be
instructed to continue taking methenamine during this
antibiotic treatment course. Details of all treatment anti-
biotic courses will be recorded including the agent used
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and the number of days that participants actually took the
prescribed antibiotic. The rate of UTI will be defined
firstly as a simple incident rate and secondly as the inci-
dent density rate as described above and annualised for
the purpose of standardisation.
Antibiotic prophylaxis
For those women randomised to receive antibiotic,
once-daily, low-dose, prophylactic antimicrobial therapy
will be prescribed for 12 months. The agent to be used
will be active against common urinary pathogens and se-
lected by the responsible clinician depending on patient
characteristics such as previous use, allergy, renal
function, liver function, prior urine cultures and local
guidance. Available evidence suggests the use of nitro-
furantoin 50 mg or 100 mg, trimethoprim 100 mg or
cefalexin 250 mg, in that order of preference. Renal
function will be determined by eGFR at baseline, and if
this is less than 45 mL/min/1.73m2 nitrofurantoin will
not be used. Patients randomised to receive antibiotic
prophylaxis will have blood samples taken at 3, 6, 9 and
12 months to monitor kidney and liver function (eGFR
and LFT). If there are any abnormalities in these tests
during the period of treatment then a further sample will
be taken at 18 months to ensure that these have re-
solved. If clinically indicated then blood tests may be
more frequent. Participants will be asked to take the
once-daily antibiotic prophylaxis as a single dose at bed-
time. If there are specific and intolerable adverse effects,
such as nausea with nitrofurantoin, or candidiasis with
cefalexin, then switching to an alternative agent would
be advised in consultation with the relevant clinician
with the reasons for the change recorded. The aim will
be to maintain participants on antibiotic prophylaxis
using any one of the three agents for as long as possible
during the 12-month treatment period within tolerance
and safety constraints. Participants intolerant of prophy-
lactic antibiotic despite trying alternative agents will
have the opportunity to discontinue the medication and
be offered an alternative treatment which may include
methenamine hippurate. This information will be re-
corded and the participant will continue on study. If a
participant in the antibiotic prophylaxis group develops
symptoms and signs suggestive of breakthrough UTI
then they will seek treatment in their usual way mostly
by contacting their GP and starting a discrete treatment
course of antibiotics following submission of a
mid-stream specimen of urine for routine culture and
also to the central laboratory. In this scenario they will
be instructed to stop the prophylactic antibiotic while
they are taking a treatment course and restart it again
the day following the last dose they take of the treatment
course. Clinicians and participants will be advised to use
a different agent for treatment than the one they are
taking for prophylaxis. Details of all treatment antibiotic
courses will be recorded including the agent used and
the number of days the participants actually took the
prescribed antibiotic. The rate of UTI will be defined
firstly as a simple incidence rate and secondly as the in-
cident density rate; the number of UTIs suffered during
the observation period minus days spent taking treat-
ment courses of antibiotics active against urinary tract
organisms. This number will be annualised for the pur-
poses of standardisation.
Standard of care for participants
This trial is pragmatic in design and, apart from random
allocation of treatment option and participant comple-
tion of diaries and questionnaires; participant care will
follow standard pathways in participating secondary care
NHS sites. Both prophylactic antibiotic and methena-
mine hippurate are licensed and approved for routine
NHS use. We will ensure that all participants have ac-
cess as desired to the use of other measures to reduce
the risk of UTI such as adequate fluid intake, avoidance
of constipation, and, for post-menopausal women, vagi-
nally administered oestrogen supplements. We will also
ensure that all participants are informed regarding the
possible benefit of other alternative options including
cranberry extract. Participants in both trial groups may
receive discrete courses of antibiotics as decided by the
responsible clinician for symptomatic UTI. Use of all
these adjunctive treatments will be recorded on CRFs.
Concomitant medication
It is the responsibility of the prescribing clinician to
check for interactions between trial drugs and other
medications.
Baseline
The following procedures will be undertaken at the
baseline visit, prior to randomisation, but after the par-
ticipant has given informed consent:
 Demographic review/document eligibility including
UTI details (stratify UTI frequency for
randomisation)
 Pre/post menopause (stratify for randomisation)
 Document adjunctive treatments, e.g. cranberry/
oestrogens/ D-mannose/probiotics
 eGFR and LFTs, plus optional sample for storage
and DNA analysis
 Health Resource Use Questionnaire
 EQ5D-5 L
 Mid-stream specimen of urine (MSU) for
microscopy and culture plus MSU for central
laboratory
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 Optional perineal swab for culture for the presence
of E.coli (central laboratory only)
Randomisation
Participants will be randomised onto the study as close
to the time of consent as possible. Participants who are
undertaking the 3-month washout will consent to the
study prior to undertaking the washout but will not be
randomised or complete the other baseline measures
until this has been completed. Their continued consent
and eligibility will be confirmed at this point.
Post randomisation
Post randomisation there will be a discussion of the trial
documentation with the participant and the trial medica-
tion will be prescribed (either methenamine hippurate
or antibiotic prophylaxis). Site staff will also go through
the instructions for what to do if the participant experi-
ences a UTI and how to complete the UTI record and
take and send the associated samples.
Once-monthly telephone calls
A member of the trial team will contact the participant
once monthly (when they are not attending a visit in
person) to check compliance, any concerns of the par-
ticipant and tolerance of their allocated investigational
medicinal product (IMP).
Face-to-face appointments at 3, 6, 9, 12, 15 and 18 months
Participants will attend a face-to-face appointment every
3 months. At this appointment the following will be
completed:
 UTI diary review
 Completion of CRF by trial staff
 MSU for microscopy and culture (plus MSU for
central laboratory)
 Optional perineal swab (central laboratory only at 6,
12 and 18 months)
 eGFR and LFTs blood tests
 Prescription for trial medication (3, 6 and 9 months
only)
At the time of UTI
At the time of the participant experiencing a UTI, they
will complete and return:
 Participant UTI record
 EQ5D 5 L
 MSU for culture and microscopy (plus MSU for
central laboratory)
 Trial staff to complete report alert after telephone
call from participant
Questionnaires sent directly to participants
A number of questionnaires will be sent directly to par-
ticipants from the central team at the Newcastle Clinical
Trials Unit. These are as follows:
 UTI Symptom Questionnaire
 EQ5D 5 L
 Health Resource Use Questionnaire
 TQSM
Microbiological methods
MSU samples will be sent to the central reference la-
boratory in universal containers pre-loaded with boric
acid at a concentration of 18 g/L (International Scientific
Supplies Ltd., Bradford, UK). Microscopy and
semi-quantitative culture of mid-stream specimens of
urine will be carried out in accordance with the UK
Standards for Microbiology Investigations [26]. The
presence of up to two isolates at ≥1 × 105 cfu/mL or one
isolate at ≥1 × 104 cfu/mL will be reported, while
bacterial counts of ≤103 cfu/mL and mixed cultures of
three isolates or more will be regarded as not significant.
Presumptive identification will be confirmed by
matrix-assisted laser desorption ionisation-time of flight
mass spectrometry, MALDI-TOF (Bruker microflex,
Coventry, UK). Disc diffusion susceptibility testing
against a panel of antimicrobial agents will be carried
out using Mueller-Hinton agar (Oxoid Limited, Basing-
stoke, UK) in accordance with the methods outlined by
The European Committee on Antimicrobial Susceptibil-
ity Testing (EUCAST) [27]. For E. coli isolates, suscepti-
bility testing will be carried out in triplicate. Perianal
swabs will be inoculated onto ChromID® CPS® Elite
media (bioMérieux, Basingstoke, UK) and examined for
the presence of E. coli after overnight incubation in
room air at 37 °C. As above, antimicrobial susceptibility
testing will be carried out in triplicate for E. coli strains
using EUCAST disc diffusion methodology [27].
Subject withdrawal
Participants have the right to withdraw from the trial at
any time without having to give a reason. Investigator
sites should try to ascertain the reason for withdrawal
and document this reason within the CRF and partici-
pant’s medical notes.
The investigator may discontinue a participant from
the trial at any time if the investigator considers it neces-
sary for any reason including:
 Pregnancy
 Participant withdrawal of consent
 Investigator’s discretion that it is in the best interest
of the participant to withdraw
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 An adverse event (AE) that renders the participant
unable to continue in the trial
 Termination of the clinical trial by the sponsor
Participants who withdraw from the trial will not be
replaced. There are three withdrawal options:
1. Withdrawing completely (i.e. withdrawal from
allocated treatment and provision of follow-up data, in-
cluding follow-up through patient healthcare records)
2. Withdrawing from the allocated treatment (moving
to the alternative treatment arm) in the trial but
allowing continued full follow up (including
questionnaires) and review by research team of
healthcare records
3. Withdrawing from the allocated treatment in the trial
and the active follow-up but allowing the research
team to follow-up through healthcare records
A proportion of participants who discontinue partici-
pation in the study will be invited to take part in the
qualitative interviews as it is important to understand
why some participants withdraw from the trial.
Definition of the end of study
The definition of the end of the trial will be the last par-
ticipant’s last follow-up visit at 18 months post random-
isation. An end-of-trial declaration will be submitted to
the REC and MHRA.
Source of bias
Selection bias will be minimised by including all adult fe-
male patients with recurrent uncomplicated UTI as eli-
gible participants. We have deliberately set few exclusion
criteria to enable the findings of this study to be generalis-
able. Both treatments are licensed for this condition, ex-
hibit a low side-effect profile. Target population and
sample size and have little interaction with other common
medications, which limits absolute contra-indications to
either therapy. We will stratify randomisation on the basis
of number of UTIs (more than four episodes per year vs
four or more episodes per year) and menopausal state
(pre-menopausal vs menopausal/post-menopausal) of the
participants to ensure equivalent proportions of these
groups at differential risk in both arms.
Eligible patients and their responsible clinicians will
need to be sufficiently uncertain of the optimum treat-
ment for rUTI to allow randomisation. The ‘Background
and Rationale’ section (sections ‘1 and 2’) of this docu-
ment sets out the existing evidence for both treatments
and describes Level-1 evidence to support the use of
both prophylactic antibiotics and methenamine hippur-
ate. Similar reductions in the frequency of episodes of
UTI are reported for both treatments and clinicians
should, therefore, have equipoise based on these data.
This should ensure that any selection bias in terms of
characteristics of rUTI sufferers put forward and willing
to be randomised compared with those who are eligible
but not willing to participate is minimised. We will keep
an anonymised screening log at each centre listing
demographic and clinical characteristics and reasons for
declining randomisation (if offered) and compare this
group with those entering and those completing the trial.
Secondly the characteristics of participants who switch
treatment arm during the 12-month treatment period
may differ from those completing the allocated strategy.
We will address this by comparison of demographic data
and QoL scores between these groups measured at base-
line prior to randomisation and following treatment.
Data handling and record keeping
Data will be collected using CRFs, participant-completed
questionnaires, UTI diaries and information retrieved
from medical notes. Data will be entered remotely at
each site into the secure validated clinical data manage-
ment system Elsevier’s MACRO by the local investigator
or another member of the site research team with
delegated responsibility for this activity. A site delegation
log of the study site personnel and their delegated study
activities will be kept in the Investigator Site File (ISF)
throughout the duration of the study. CRFs,
participant-completed questionnaires and UTI diaries
which are entered into eCRFs in the MACRO database
at a later date will be classed as source documentation.
Results of urine and perineal swab analysis will be
uploaded securely into the MACRO database by the
database manager from reports produced by the central
laboratory. Data will be handled, computerised and
stored in accordance with the Data Protection Act
1998 and the General Data Protection Regulation
(GDPR) from 25 May 2018. Under the trial participant
consent, identifiable data will be stored in a separate,
password-protected database within Newcastle Clinical
Trials Unit (NCTU), with access limited to those
members of the trial team responsible for the prepar-
ation and sending of follow-up questionnaires and log-
ging their return. This database will also be used to
maintain a record of each participant’s preferred
method of communication with the trial team, and to
ensure that trial correspondence is sent to each partici-
pant using their preferred mode of delivery. The
quality and retention of study data will be the respon-
sibility of NCTU. All study data will be retained in ac-
cordance with the latest Directive on Good Clinical
Practice (GCP) and local policy.
Questionnaires returned by post to the trial manage-
ment office in Newcastle will be entered by the trial
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administrative team at NCTU. The NCTU trial ,man-
agement team in collaboration with the database man-
ager will work closely with local site research teams to
ensure that the data are as complete and accurate as
possible. The NCTU trial management team will be re-
sponsible for chasing missing data with sites. Two re-
minders will be sent to participants to prompt return of
questionnaires. Extensive range and consistency checks
are done to enhance the quality of the data.
Access to data and data security
Caldicott approval for use, transfer and storage of partici-
pant identifiable information will be obtained at each site.
All research data will be kept in accordance with
Newcastle University’s information security policy (http://
www.ncl.ac.uk/itservice/policies/). Newcastle University
maintains a series of regular backups and off-site mirror
servers to ensure continuity and disaster recovery.
Elsevier’s MACRO database is an electronic data cap-
ture system which complies with the requirements of
regulatory bodies and maintains an audit trail of any
changes to the data. All data stored in MACRO benefit
from Elsevier’s hosting service in collaboration with
Rackspace which features redundancy and backup mea-
sures in case of disaster. Users have password-limited ac-
cess to the MACRO database, which restrict access to
their own particular role and site.
Data collected during the course of the research will
be kept strictly confidential and accessed only by mem-
bers of the trial team. Participant’s details will be stored
on a secure database under the guidelines of the Data
Protection Act 1998 and the General Data Protection
Regulation (GDPR) from 25 May 2018. Participants will
be allocated a unique trial number at randomisation
which will be used on all study-related forms and ques-
tionnaires throughout the duration of the study. This
will also allow anonymised versions of the secure data-
base to be available to the trial team and subsequently
processed for archiving. Personal data will not be kept
for longer than is necessary for the purpose for which it
has been acquired.
Discontinuation rules
Data will be analysed at the end of the study; there are
no planned interim analyses. An independent Data Mon-
itoring Committee (DMC) will be convened to under-
take independent review. The purpose of this committee
will be to monitor efficacy and safety endpoints and will
operate according to a written terms of reference linked
to the DAMOCLES Charter. Only the DMC will have
access to full un-blinded study data, if requested, prior
to completion of the trial. All analyses will follow a care-
fully documented Statistical Analysis Plan (SAP). The
DMC will be asked to review and comment on this plan
prior to analysis. A single main analysis will be per-
formed at the end of the trial when all follow-up has
been completed. The DMC will meet initially to agree
terms of reference and other procedures. The final trial
report will contain full detail of the analytical method-
ology. The DMC will meet at least three times, at the
start, middle and completion of the study. At the first
meeting, the Committee will agree on its charter of op-
eration, and discuss and advise on the inclusion of an in-
terim analysis and possible adoption of a formal
stopping rule for efficacy or safety.
Assessment of study adherence
Some participants or their clinicians will seek to change
their allocated group at some point during trial partici-
pation either due to lack of efficacy or adverse effects for
either treatment. Trial literature will emphasise the need
to adhere to the allocated strategy during the 12-month
trial period if possible and will record any deviation.
Multiple switching between prophylactic antibiotic
agents will be allowed. If participants do stop their allo-
cated treatment within the 12-month treatment period
or if they re-commence prophylaxis during the subse-
quent 6-month observation period this will be recorded
and the participant will continue on study unless they
withdraw consent.
Sample size calculation
The clinical trial has a planned recruitment target of 240
patients, 120 in each of the treatment arms. If there is
an actual difference of 0.6 episodes (in favour of treat-
ment with antibiotics), then two groups of 87 patients
are required to be 90% sure that the lower limit of a
one-sided 95% confidence interval (or equivalently a
90% two-sided confidence interval) will be above the
non-inferiority limit of one UTI episode assuming a
standard deviation of 0.9 episodes per year. Total sample
size assuming two groups and an attrition rate of 25% =
232, rounded up to 240.
We have discussed extensively the relative merits of
non-inferiority against superiority comparison and be-
lieve the key issue is that an orally administered urinary
antiseptic would be acceptable to the patient group pro-
vided that their effectiveness for UTI prevention is no
worse than antibiotic prophylaxis and that the burden of
adverse effects is similar or better. There is also the key
added potential benefit of reduced rates of resistant or-
ganisms and subsequent collateral harm to the individ-
ual and the community. The sample size calculation is
based on the following assumptions:
 Semi-structured interviews with a patient panel of
12 women identified that any reduction in UTI
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episodes even by one per year would be deemed
worthwhile. Therefore, we have set the minimum
clinically important difference between the
treatment arms of one UTI per 12 months as our
non-inferiority margin
 The two existing meta-analyses of studies examining
prophylactic antibiotics [6] and methenamine hippur-
ate [7] have quoted mean relative risk of UTI vs pla-
cebo of 0.15 and 0.24, respectively. Using these values
and data from a local audit (unpublished, n = 200)
suggesting that the average number of UTI episodes
per year in this patient group is 6.5, we have estimated
that the difference in number of episodes per year be-
tween prophylactic antibiotics and methenamine hip-
purate to be 0.6 episodes (in favour of antibiotics)
 The standard deviation of episodes of UTI per year is
taken from the placebo groups in the studies included
in the Cochrane meta-analyses [4, 10] and has been
conservatively estimated at 0.9 episodes per year
 The type-1 error rate for a two group comparison is
set at 5%, thus the calculation of a one-sided 95% confi-
dence interval (or a two-sided 90% confidence interval)
 The attrition rate of participants in this study has
been conservatively estimated at 25%
Statistical analysis
The main analysis will comprise a comparison of pa-
tients randomised to antiseptic with patients randomised
to antibiotic (‘intention to treat’).The primary clinical
outcome is the occurrence of symptomatic UTI during
the 12-month period of treatment. Our hypothesis is
that treatment with antiseptic is not inferior to treat-
ment with antibiotic. When considering an inferiority
limit the variable that patients most readily relate to is
the number of episodes experienced during treatment.
The inferiority limit adopted for this study will be one
episode per year. A 90% confidence interval for the dif-
ference between groups (antibiotic minus antiseptic) will
be calculated using a resampling (bootstrap) procedure.
Provided that the lower 90% confidence limit is greater
than the pre-specified non-inferiority limit (here − 1 for
this definition of difference as a higher (worse) value in
the antiseptic group would result in a negative differ-
ence), we will infer that treatment with antiseptic is not
inferior to treatment with antibiotic.
A secondary analysis of the primary outcome will in-
volve the modelling of the number of episodes of UTI
using a negative binomial regression model with differ-
ences between centre included as a random effect and a
binary indicator of previous annual frequency of UTI at
baseline (more than four episodes vs four or less epi-
sodes) and menopausal status (pre-menopausal vs meno-
pausal/post-menopausal) will be included as fixed
effects. This will yield an estimate of the incidence rate
ratio. A binary indicator of at least one patient-reported
or clinician-recorded symptom of UTI will be analysed
using the same approach but with a binomial error
structure. The same methods will be used to analyse the
relative frequency of episodes of UTI during the
6-month post-treatment period as a secondary outcome.
Analysis of the secondary outcomes will follow a
broadly similar strategy although non-inferiority will not
be assessed as this is only relevant for the pre-specified
primary outcome. Incidence or occurrence type out-
comes will be analysed in a manner analogous to that
previously described for the primary outcome. Patient
satisfaction will be compared between arms using an
analysis of variance/covariance approach adjusting for
stratification variables and other predefined baseline co-
variates. Health-related QoL will be analysed as part of
the health economics analysis.
We will also undertake a per-protocol analysis. The
primary analysis will be repeated but on the subset of
patients who have been treated in accordance with the
treatment protocol for the arm to which they were ran-
domised. Patients who switch treatments will still be
analysed within the group to which they were rando-
mised but only if that switching has been undertaken in
accordance with the specified protocol.
A full SAP will be produced and finalised prior to data
lock and analysis commencing.
Qualitative substudy
In the embedded qualitative study which we propose to
conduct in the early phase of recruitment, we will carry
out in-depth telephone interviews with up to 15 patients
in each of three groups (those who agree to participate,
those who decline and, if available, those who drop out
of the study before the end of the follow-up period).
Also, we will conduct telephone interviews with up to
eight clinicians recruiting to the trial. This will provide
information regarding both patients’ willingness to be
randomised and clinicians’ views on treatment random-
isation. A descriptive report with proposed action will be
prepared and sent to the Trial Steering Committee
(TSC) for approval this will include rate and reasons of
declining randomisation and participant attrition.
Qualitative analysis
Topic guides for both patient and clinician telephone in-
terviews will be developed with the input of the study
team and Patient and Public Involvement (PPI) group.
Interviews will be digitally recorded with the permission
of the interviewee and transcribed verbatim. NVivo will
be used as a tool to manage and code the transcript data.
Data will be analysed drawing upon the constant com-
parative method. Issues identified that impact on recruit-
ment and are resolvable, such as lack of clarity in the
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patient study information or consent process, will be ad-
dressed immediately. We plan the headline results to be
available to inform change in study procedures at an
early stage of the recruitment phase.
Health economics analysis
A ‘within-trial’ and model-based economic evaluation
will be conducted. These analyses will take the form of a
cost-utility analysis. The within-trial analysis will take
the perspective of the NHS and personal and social ser-
vices, but will also take a wider perspective by including
costs by the participants and their families. The
model-based analysis will take the perspective of the
NHS and personal and social services.
Within-trial analysis
For each trial participant the use of health and social care
services will be recorded. The use of services for the initial
treatments (medications), including time in hospital, will
be collected on the CRF. Also collected on the CRF will
be the use of secondary care services such as duration of
any hospital stay, number of outpatient visits, use of tests,
and any change in medications. Use of primary care ser-
vices, such as GP visits, will be collected via questionnaire
at baseline, 3, 6, 9, 12 and 18 months. Information of fur-
ther patient costs will be sourced from other relevant
RCTs that collected patient costs due to the burden on re-
spondents from collecting this type of data.
Costs for healthcare services will be obtained from
standard sources such as NHS reference Healthcare Re-
source Group (HRG) tariffs, the British National Formu-
lary25 (BNF) for medications, and Unit Costs of Health
and Social Care [20] for primary care usage. Further data
will come from the study centres themselves such as the
cost of consumables and other equipment used for treat-
ment. The price-year adopted for the base-case analysis
will be the year when the final analysis is conducted. For
each participant measures of use of resources will be com-
bined with unit costs to provide a cost for that participant.
The relative changes in health-related QoL resultin
from reductions in recurrent UTIs, together with any
harms associated with each of the treatment strategies
and with subsequent treatments for UTIs, will be cap-
tured by the EQ5D-5 L. Tariffs will be used to provide
values so that the EQ5D-5 L data can be used for
decision-making [25]. Health State Utilities from the
EQ5D-5 L will be used to estimate QALYs for each par-
ticipant using the area-under-the-curve approach.
Data on costs and QALYs will be used to estimate the
mean cost and QALYs for each intervention group. The
cost and QALY data will then be used to estimate incre-
mental costs and QALYs and incremental costs per QALY.
These data will be presented as point estimates and boot-
strapping techniques will be used to estimate the statistical
imprecision surrounding them. The results of this stochas-
tic analysis will be presented as cost and QALY plots and
as cost-effectiveness acceptability curves [21].
Model-based analysis
Drawing upon existing modelling expertise in the Health
Economics Group at Newcastle University, an economic
model describing recurrent UTIs will be developed. The
model will be constructed following guidelines for best
practice in economic modelling [22].
The use of services both for the treatment and manage-
ment for recurrent UTIs will be modelled and the costs of
these events will be based upon the estimates for these
events derived from within the trial. The trial-based data
will be the main source of data for the economic model
but it will be supplemented by focussed searches of the lit-
erature and health economic databases (e.g. the Centre for
the Evaluation of Value and Risk in Health (CEVR) Cost Ef-
fectiveness Analysis (CEA) Registry; NHS Economic Evalu-
ation Database).
Discounting will be applied to costs and outcomes at
the UK-recommended rate of 3.5% [23]. Further data re-
quired for the model relate to the transition and other
probabilities of events occurring over the lifetime of pa-
tients. These probabilities include the risk of recurrence
as well as probabilities of receiving different types of
intervention should recurrence occur.
The model will be used to produce estimates of costs
and QALYs (from the EQ5D-5 L). Cost-effectiveness will
be reported as incremental cost per QALY gained (at
both 12 months and over the patient’s lifetime). The
model will be probabilistic and distributions will be at-
tached to all parameters, the shape and type of distribu-
tion will depend upon the data available and
recommendations for good practice in modelling [24].
The results will also be presented as point estimates of
costs, effects, incremental costs, QALYS and measures
cost-utility. They will also be presented as plots of costs
and QALYs derived from the probabilistic analysis and
cost-effectiveness acceptability curves. Deterministic
sensitivity analyses will be combined with the probabilis-
tic analysis to explore other forms of uncertainty.
Trial monitoring
Monitoring of study conduct and data collected will be
performed by a combination of central review and site
monitoring visits to ensure that the study is conducted
in accordance with GCP. Study site monitoring will be
undertaken by members of the Trial Management Group
(TMG). The main areas of focus will include consent,
serious adverse events (SAEs) and essential documents
in study. Site monitoring will include:
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 All original consent forms will be reviewed as part
of the study file; confirmation of the presence of a
copy in the patient hospital notes may be requested
for 10% participants
 All original consent forms will be compared against
the study participant identification list
 All reported SAEs will be verified against clinical
records (Source Data
Verification (SDV))
 The presence of essential documents in the ISF and
study files will be checked
 Verification of primary endpoint data and eligibility
data for 10% of participants entered in the study
may be requested
Central monitoring will include:
 All applications for study authorisations and
submissions of progress/safety reports will be
reviewed for accuracy and completeness, prior to
submission
 All documentation essential for study initiation will
be reviewed prior to site authorisation
 Statistical monitoring for outlier sites and unusual
data patterns
All monitoring findings will be reported and followed
up with the appropriate personnel in a timely manner.
Adverse events (AEs) occurring during trial participa-
tion will be recorded and reported in line with GCP guide-
lines. The expected rate of AEs is low for both treatment
arms. All non-serious adverse reactions (ARs) will be re-
corded in the study database for the duration of the trial.
Any SAEs or serious adverse reactions (SARs) will be re-
corded throughout the duration of the trial in the study
database and on the specific trial SAE form.
The trial may be subject to audit by representatives of
the sponsor (Newcastle upon Tyne Hospitals NHS
Foundation Trust) or inspection by the MHRA or HTA.
Each investigator site will permit trial-related monitor-
ing, audits and regulatory inspection including access to
all essential and source data relating to the trial.
Trial reporting
Final data cleaning and preparation of tables for analysis,
and writing of Background and Methodology sections of
the report will commence at month 30 but the results
will not be communicated to the PMG and TSC by the
trial statistician until after the end of follow-up phase at
month 48. These data will be available to the DMC on
request or when indicated by the trial statistician.
During this period the health economics team will prepare
the structure of the cost-effectiveness analyses using dummy
and actual data as it becomes available. Final analysis to-
gether with preparation of the introduction and method-
ology sections of the report and associated peer-reviewed
publication will then be performed during months 47–54
with finalisation of the report by end of month 55.
Dissemination and outputs
The results of the study will be presented at topic-specific
national/international conferences and be published in a
general medical, infectious diseases or urology themed
peer-reviewed journal. The trial will provide high-level
evidence to use in new or updates of existing systematic
reviews such as those published by Cochrane.
The most significant anticipated outcome from this
study will be demonstration of the efficacy of a
non-antibiotic treatment for the prevention of recurrent
UTIs, methenamine hippurate. If our hypothesis holds
true the study will represent a significant step forward in
the treatment of recurrent urinary infection, with
high-level evidence for the use of a treatment strategy
that avoids prolonged antibiotic use which is directly in
line with the UK Government’s strategy to combat anti-
microbial resistance. It is likely that national and inter-
national media will pick up the story and inform the
wider public of the results and their significance. We will
also engage with relevant NHS managers and other trust
representatives to facilitate prompt changes in local
practice and promote this alternative preventative treat-
ment for recurrent UTIs. The results will be publicised
on both hospital websites and discussed at departmental
meetings. The results will be disseminated to members
of professional groups, such as BAUS and EAU, through
updates and presentations.
Participants will be provided with a lay summary of re-
sults. They will also have access to a copy of journal arti-
cles through the trial website. Members of our PPI focus
groups will review results and they will be involved in
writing lay summaries of results for dissemination to
relevant patient groups such as the Cystitis and Over-
active Bladder Foundation (COB) and the Bladder and
Bowel Foundation. We will utilise the COB expertise on
how best to deliver these results to the other participants
and patient-specific groups. These will be in accessible
formats in keeping with equality legislation.
SPIRIT
This protocol has been written in accordance with the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines. Please refer to the
SPIRIT Checklist and Figure (Fig. 2) submitted alongside
this publication for further details (see Additional file 1).
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STUDY PERIOD
Enrolment Allocation Post-allocation Follow up
TIMEPOINT Screening Baseline 3 months
6 
months
9 
months 
12 
months
At time 
of UTI
Monthly 
checks 15 months 18 months
ENROLMENT:
Demographics X X*
Concomitant 
medications X X*
Eligibility 
assessment X
Informed consent X
Medical history X
Physical 
examination X
CRF completion X X X X X X X X X X
Randomisation X
Dispensing of trial 
drugs X X X X
Qualitative 
interviews X** X***
INTERVENTIONS:
Dispensing of trial 
drugs X X X X
eGFR and LFTs (a 
sample for DNA 
will be taken at 
one of these time 
points)
X X* X X X X X X
MSU (local lab) X X X X X X X X
MSU (central lab) X X X X X X X X
Perineal swab X X X X
ASSESSMENTS:
Compliance X X X X X X X X
UTI Record X
UTI questionnaire X X X X X X
EQ5D-5L X X X X X X X X
Health Resource 
Use Questionnaire X X X X X X
TQSM X X
Adverse event 
assessments X X X X X X X
*Screening data values may be used for baseline if taken within 14 days from date of randomisation. 
**15 patients who declined to participate in main study but consented to interview study.
***15 patients who do not complete the treatment and 15 patients who stay in the study up to 6 months post randomisation will be interviewed. 
Time points will vary
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure for the ALTAR trial
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Discussion
As a pragmatically designed trial, apart from randomisa-
tion to one of the treatment options and participant
completion of diaries and questionnaires; participants
will follow standard care pathways in NHS secondary
care. Both prophylactic antibiotics and methenamine
hippurate are licensed and approved for routine NHS
use against rUTI and are standard care for this indica-
tion. Therefore, is it considered that the risk associated
with trial participation is no higher than that of standard
care. On this basis the trial was submitted to MHRA
and given authorisation as a ‘Type A’, low-risk,
notification-only study. A research study providing ro-
bust evidence of at least no-worse effectiveness for
non-antibiotic treatment is needed to inform choices of
alternative treatments to prolonged antibiotic use. This
study aims to provide this in the context of a routine
NHS care setting and it is hoped the pragmatic nature
of the trial will ensure the generalisability of the results
to the patient group that is the focus of this study.
Trial status
Recruitment was ongoing at the point of submission.
Since submission, the ALTAR trial has recruited to tar-
get ahead of expected time.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents. (DOC 119 kb)
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